Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01279291 · ClinicalTrials.gov registry record · Phase 1
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
A Phase 1 study, sponsored by Kyowa Kirin Co..
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT01279291 is a Phase 1 study that was terminated before completion, run by Kyowa Kirin Co.. The registered enrollment target is 22 participants.
The verdict
NCT01279291, a Phase 1 study, was terminated before completion, sponsored by Kyowa Kirin Co..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is a two-part, Phase 1, open-label, multicenter, dose escalation study of KHK2866 as monotherapy in patients with advanced solid tumors, and in combination with chemotherapy in subjects platinum-sensitive and platinum-resistant ovarian cancer.
Interventions
- DRUG pegylated liposomal doxorubicin
- DRUG paclitaxel
- BIOLOGICAL KHK2866
- DRUG Gemcitabine and Carboplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01279291
The ClinicalTrials.gov registry entry for NCT01279291 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyowa Kirin Co., which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which pegylated liposomal doxorubicin is the first listed.
NCT01279291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01279291 about?
NCT01279291 is a clinical study titled "Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer". This is a two-part, Phase 1, open-label, multicenter, dose escalation study of KHK2866 as monotherapy in patients with advanced solid tumors, and in combination with chemotherapy in subjects platinum-sensitive and platinum-resistant ovarian cancer.
What is the current status of trial NCT01279291?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2011-01. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01279291?
The interventions under investigation include: pegylated liposomal doxorubicin (DRUG), paclitaxel (DRUG), KHK2866 (BIOLOGICAL), Gemcitabine and Carboplatin (DRUG).
Who is sponsoring clinical trial NCT01279291?
This trial is sponsored by Kyowa Kirin Co., which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.